Beam Therapeutics Inc.
(NASDAQ:BEAM)
$28.23
-0.35 (-1.24%)
Open: 2:55 PM
BEAM Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
BEAM Stock Price Today
Beam Therapeutics Inc. (BEAM) stock declined over -5.31% intraday to trade at $28.19 a share on NASDAQ. The stock opened with a loss of -33.66% at $19.75 and touched an intraday high of $19.75, falling -5.31% against the last close of $29.77. The Beam Therapeutics Inc. in stock market went to a low of $18.44 during the session.
BEAM Stock Snapshot
$29.77
Prev. Close
2.33 Billion
Market Cap
$18.44
Day Low
$19.75
Open
N/A
Number of Shares
$19.75
Day High
N/A
P/E ratio
-4.18
EPS (TTM)
12.80
Cash Flow per Share
N/A
Free Float in %
10.09
Book Value
537751.00
Volume
BEAM Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Company Information
EmployeesN/A
Beta1.73
Sales or Revenue$81.55 Million
5Y Sales Change43193.50%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Peers
Frequently Asked Questions
What is the current Beam Therapeutics Inc. (BEAM) stock price?
Beam Therapeutics Inc. (NASDAQ: BEAM) stock price is $28.19 in the last trading session. During the trading session, BEAM stock reached the peak price of $19.75 while $18.44 was the lowest point it dropped to. The percentage change in BEAM stock occurred in the recent session was -5.31% while the dollar amount for the price change in BEAM stock was -$1.58.
BEAM's industry and sector of operation?
The NASDAQ listed BEAM is part of Biotechnology industry that operates in the broader Healthcare sector. Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.
Who are the executives of BEAM?
Mr. John M. Evans M.B.A.
Chief Executive Officer & Director
Ms. Terry-Ann Burrell M.B.A.
Chief Financial Officer & Treasurer
Mr. Brian Riley
Senior Vice President of Technical Operations
Dr. Giuseppe Ciaramella Ph.D.
Pres & Chief Scientific Officer
How BEAM did perform over past 52-week?
BEAM's closing price is 0.20% higher than its 52-week low of $16.95 where as its distance from 52-week high of $54.3 is -0.55%.
How many employees does BEAM have?
Number of BEAM employees currently stands at N/A. BEAM operates from 238 Main Street, Cambridge, MA 02142, US.
Link for BEAM official website?
Official Website of BEAM is: https://www.beamtx.com
How do I contact BEAM?
BEAM could be contacted at phone #857 327 8775 and can also be accessed through its website. BEAM operates from 238 Main Street, Cambridge, MA 02142, US.
How many shares of BEAM are traded daily?
BEAM stock volume for the day was 537751.00 shares. The average number of BEAM shares traded daily for last 3 months was 1.27 Million.
What is the market cap of BEAM currently?
The market value of BEAM currently stands at $2.33 Billion with its latest stock price at $28.19 and N/A of its shares outstanding.